Who are we?
We are Exploring Health LLC. We are pioneers in the anti-metastasis field who engage in anti-cancer drug screening and the development of novel anti-metastatic drugs. Our research team includes outstanding and passionate clinicians, biotechnologists, and pharmacologists from all over the world. Driven by our vision: "blocking cancer metastasis and saving more lives", we are committed to exploring and discovering leading compounds that can be developed into anti-metastatic drugs for clinical applications which will benefit numerous cancer patients.
Cancer cell metastasis is the leading cause of cancer patient death. Approximately 90% of cancer patient deaths are caused by cancer cell metastasis. However, most clinical anti-cancer drugs are currently designed to inhibit the proliferation of cancer cells. There is a lack of drugs specifically designed to block cancer cell metastasis, and there is no commercial high-throughput screening platform for efficiently identifying novel anti-metastatic drugs either. Future anti-tumor therapeutic strategies must adopt growth inhibitors, in combination with anti-metastasis drugs to treat advanced cancer patients, which will greatly improve the curative rate of cancer and significantly prolong patients’ survival time. At Exploring Health LLC, we have successfully developed a high-throughput screening platform that can rapidly and efficiently identify anti-metastatic leading compounds. With our innovative high-throughput technology platform for screening anti-metastatic drugs, we are fully committed to developing anti-metastatic drugs to provide the medical industry with novel anti-cancer therapeutic strategies, which will revolutionize cancer therapeutics and significantly prolong patients’ survival time.
